Enanta (ENTA) officer gains stock from PSU and rTSR awards, with tax forfeiture
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported equity compensation transactions in Enanta common stock. On February 12, 2026, she acquired 1,575 shares through performance share units that vested based on 2024-2025 research and development milestones, as determined by the Compensation Committee. She also acquired 4,987 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index over matching 60-day periods two years apart. To cover withholding taxes from these awards, 3,257 shares were automatically forfeited at a price of $14.25 per share. Following these transactions, she directly held 33,925 shares of Enanta common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Kieffer Tara Lynn
Role
Chief Product Strategy Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,575 | $0.00 | -- |
| Grant/Award | Common Stock | 4,987 | $0.00 | -- |
| Tax Withholding | Common Stock | 3,257 | $14.25 | $46K |
Holdings After Transaction:
Common Stock — 32,195 shares (Direct)
Footnotes (1)
- Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026. Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026. Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
FAQ
What insider transactions did ENTA’s Chief Product Strategy Officer report?
Tara Lynn Kieffer reported equity compensation transactions in Enanta common stock. She received vested shares from performance-based awards and had a portion of shares automatically forfeited to cover withholding tax obligations related to those awards.
What performance metrics triggered the PSU vesting for Enanta (ENTA)?
The performance share units vested based on research and development milestones over the 2024-2025 calendar period. Enanta’s Compensation Committee evaluated performance against these two-year milestones before the units settled into common stock on February 12, 2026.
How was the relative total stockholder return award measured for ENTA?
The rTSRU award was tied to Enanta’s total stockholder return versus component companies in the Nasdaq Biotech Index. Performance was measured over the same 60-day calendar periods two years apart, with results determined by the Compensation Committee before share settlement.
What is the role of Enanta’s Compensation Committee in these ENTA awards?
Enanta’s Compensation Committee determined whether performance conditions were met for both the performance share units and the relative total stockholder return award. Their assessment governed vesting outcomes and the resulting share issuances on February 12, 2026.